Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Gross Margin (2016 - 2025)

Guided Therapeutics' Gross Margin history spans 16 years, with the latest figure at 77.63% for Q4 2025.

  • On a quarterly basis, Gross Margin rose 27763.0% to 77.63% in Q4 2025 year-over-year; TTM through Dec 2025 was 74.58%, a 4600.0% increase, with the full-year FY2025 number at 74.45%, up 4587.0% from a year prior.
  • Gross Margin hit 77.63% in Q4 2025 for Guided Therapeutics, up from 58.33% in the prior quarter.
  • Over the last five years, Gross Margin for GTHP hit a ceiling of 100.0% in Q2 2021 and a floor of 200.0% in Q4 2024.
  • Historically, Gross Margin has averaged 36.54% across 5 years, with a median of 67.09% in 2024.
  • Biggest five-year swings in Gross Margin: plummeted -27167bps in 2021 and later surged 27763bps in 2025.
  • Tracing GTHP's Gross Margin over 5 years: stood at 68.33% in 2021, then soared by 46bps to 100.0% in 2022, then crashed by -50bps to 50.0% in 2023, then crashed by -500bps to 200.0% in 2024, then skyrocketed by 139bps to 77.63% in 2025.
  • Business Quant data shows Gross Margin for GTHP at 77.63% in Q4 2025, 58.33% in Q3 2025, and 67.52% in Q2 2025.